Carson City, Nevada, March 28, 2017, Cell MedX Corp. (OTCQB: CMXC), (“Cell MedX” or the “Company”), announced that it has completed its registration process with U.S. Food and Drug Administration (“FDA”) and has initiated an application process to receive FDA…
Cell MedX Corp. Announces First Subjects Screened and Qualified for the Observational Clinical Trial
CARSON CITY, NV / March 9, 2017 / Cell MedX Corp. (CMXC), (“Cell MedX” or the “Company”), is pleased to announce that Dr. Richard Tytus, the Lead Investigator on the previously announced Observational Clinical Trial (the “Trial”), and his team…
Carson City, Nevada, March 1, 2017, Cell MedX Corp. (OTCQB: CMXC), Cell MedX Corp. (“Cell MedX” or the “Company”), is happy to announce that it has received an approval from the Ethics Review Board to commence its observational clinical trial…